Stockreport

InspireMD Reports 94% Increase in CGuard™ EPS Revenues for the Second Quarter of 2018

InspireMD Inc.  (NSPR) 
NASDAQ:AMEX Investor Relations: inspiremd.com/en/investors/investor-relations
PDF TEL AVIV, Israel, Aug. 06, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American:NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention o [Read more]